儿科住院的差异是因为生长不稳定
Katherine Salada1,2, Jodi Ehrmann1,2, Harlan McCaffery2
1Division of Pediatric Hospital Medicine, University of Michigan, Mott Children's Hospital, Ann Arbor, Michigan.
Hospital pediatrics
|March 9, 2026
概括
与白人儿童相比,生长迟缓 (GF) 的黑人儿童在照顾方面经历了差异,呈现出较低的体重相对于年龄的z分数和增加的社会工作和儿童保护服务转介.
科学领域:
- 儿科健康 儿科健康
- 健康差异 在健康上的差异
- 增长障碍 发展障碍 发展障碍
背景情况:
- 增长迟缓 (GF) 影响全球儿童,基于种族,种族和社会经济地位的潜在差异在照顾中.
- 了解这些差异对于公平的医疗保健服务至关重要.
研究的目的:
- 调查在诊断为GF的儿童的入院标准和住院治疗中的种族,种族和社会经济差异.
- 在实验室测试,咨询和干预中识别特定模式.
主要方法:
- 对2012-2022年被诊断患有GF的1-24个月龄儿童的医疗记录的回顾性审查.
- 对人口统计数据,生长参数 (体重与年龄的z分数 - WFAZ) 和住院治疗的分析.
- 用于数据分析的概括估计方程与逻辑链接.
主要成果:
- 这项研究包括982个接触者 (890个独特的患者),主要是白人 (69%) 和医疗补助受益者 (60%).
- 与白人患者相比,黑人患者的区域剥夺指数得分较高,入院/出院WFAZ较低.
- 黑人患者的社会工作咨询和儿童保护服务推增加,而白人患者的哺乳咨询率更高.
结论:
- 基于种族和社会经济地位的咨询中,观察到有明显差异的儿童接受了GF.
- 黑人患者呈现更严重的GF (较低的WFAZ),与增加的社会工作和CPS转诊相关.
- 需要进行进一步的研究,以解决导致儿科GF护理差异的因素.
相关概念视频
01:10Nature and Nurture
22.6K
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.6K
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
411
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
605
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
345
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
345
01:29Drug Dosing: Infants and Children
645
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
645
01:27Signs of Puberty
1.8K
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.8K